Notably, a structurally similar compound with enhanced pharmokinetic properties, IMCB7839 (Aderbasib), has undergone phase I/II clinical trials in patients with HER2-positive breast cancer, in combination with Herceptin (trastuzumab). Here, ERBB2 is linked to breast cancer.